Table 4.
Knockdown and 24 h delayed mortality in susceptible Ae. aegypti for different formulations.
| Time interval |
Formulation code |
Deltamethrin content w% |
KD60min % (N) | KDT10 (95% CI) | KDT50 (95% CI) | Slope (±) | χ2 (p) | R | CM24 h (%) |
|---|---|---|---|---|---|---|---|---|---|
| T0 | WSRIP-1 | 0.24# | 98 (50) | 13.7 (12.1–15.1) | 23.1 (21.6–24.6) | 5.6 ± 0.4 | 10.9 (0.3) | 0.98 | 100 |
| WSRIP-2 | 0.44# | 100 (50) | 6.1 (4.6–7.6) | 16.2 (14.3–18.0) | 3.1 ± 0.3 | 10.7 (0.1) | 0.96 | 100 | |
| WSRIP-3 | 0.59# | 100 (42) | 4.0 (2.2–5.6) | 13.4 (11.2–16.0) | 2.8 ± 0.4 | 3.5 (0.3) | 0.96 | 100 | |
| T6 | WSRIP-3 | 0.31& | 100 (41) | 6.8 (5.2–8.3) | 15.2 (13.4–16.9) | 3.7 ± 0.4 | 5.4 (0.5) | 0.99 | 97.6 |
| T12 | WSRIP 3 | 0.24& | 98 (50) | 6.9 (5.4–8.4) | 18.1 (16.2–19.9) | 3.1 ± 0.2 | 12.9 (0.2) | 0.97 | 94 |
| T18 | WSRIP 3 | 0.19& | 94 (50) | 7.4 (5.6–9.1) | 22.1 (19.7–24.3) | 2.7 ± 0.2 | 8.6 (0.6) | 0.97 | 90 |
T0, at the time of application; T6/T12/T18, 6/12/18 months post-application; CM24 h, Corrected mortality post 24 h exposure; KDT, knockdown time; CM24 h, 24 h corrected mortality;
#
calculated,
&
estimated by HPLC; p significant if < 0.05.